ผลงานวิจัยหน่วยมะเร็งวิทยา (Oncology)

Division of Medical Oncology หน่วยมะเร็งวิทยา

2023 (21)

1. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

   Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. J Clin Oncol. 2023 Feb 1;41(4):790-802.

• Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.

  Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. Ann Oncol. 2023 Mar;34(3):251-261.

• Clinical and immunological characteristics for BK polyomavirus-associated nephropathy after kidney transplantation.

  Siripoon T, Apiwattanakul N, Mongkolrattanakul P, Tongsook C, Unwanatham N, Hongeng S, Kantachuvesiri S, Bruminhent J. Immun Inflamm Dis. 2023 Aug;11(8):e956.

• Six-MicroRNA Prognostic Signature in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.

  Worakitchanon W, Panvongsa W, Siripoon T, Kitdumrongthum S, Wongpan A, Arsa L, Trachu N, Jinawath N, Chairoungdua A, Ngamphaiboon N. JCO Precis Oncol. 2023 May;7:e2300003.

• Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.

  Ngamphaiboon N, Chairoungdua A, Dajsakdipon T, Jiarpinitnun C. Oral Oncol. 2023 Oct;145:106520.

• CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients.

  Majam T, Sukasem C, Reungwetwattana T, Chansriwong P, Atasilp C, Trachu N, Thamrongjirapat T, Sukprasong R, Meanwatthana J. Front Pharmacol. 2023 Nov 6;14:1222435.

• Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients.

  Khiewngam K, Oranratnachai S, Kamprerasart K, Kunakorntham P, Sanvarinda P, Trachu N, Pimsa P, Wiwitkeyoonwong J, Thamrongjirapat T, Dejthevaporn T, Sirachainan E, Reungwetwattana T. Front Oncol. 2023 Feb 21;13:1047644.

• Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV).

  Schilling WHK, Jittamala P, Watson JA, Ekkapongpisit M, Siripoon T, Ngamprasertchai T, Luvira V, Pongwilai S, Cruz C, Callery JJ, Boyd S, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Piaraksa N, Suwannasin K, Hanboonkunupakarn P, Hanboonkunupakarn B, Sookprome S, Poovorawan K, Thaipadungpanit J, Blacksell S, Imwong M, Tarning J, Taylor WRJ, Chotivanich V, Sangketchon C, Ruksakul W, Chotivanich K, Teixeira MM, Pukrittayakamee S, Dondorp AM, Day NPJ, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Elife. 2023 Feb 21;12:e83201.

• Dynamics of Different Classes and Subclasses of Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and CoronaVac Vaccination in Thailand.

  Poolchanuan P, Matsee W, Sengyee S, Siripoon T, Dulsuk A, Phunpang R, Pisutsan P, Piyaphanee W, Luvira V, Chantratita N. mSphere. 2023 Feb 21;8(1):e0046522.

• Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV).

  Jittamala P, Schilling WHK, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, Almeida PJ, Ekkapongpisit M, Cruz C, Callery JJ, Boyd S, Anunsittichai O, Hongsuwan M, Singhaboot Y, Pagornrat W, Tuntipaiboontana R, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Keayarsa S, Madmanee W, Aguiar RS, Santos FM, Batty EM, Hanboonkunupakarn P, Hanboonkunupakarn B, Sookprome S, Poovorawan K, Imwong M, Taylor WRJ, Chotivanich V, Sangketchon C, Ruksakul W, Chotivanich K, Pukrittayakamee S, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. J Infect Dis. 2023 Nov 11;228(10):1318-1325.

• Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma.

  Incharoen P, Jinawath A, Arsa L, Kamprerasart K, Trachu N, Monnamo N, Khiewngam K, Muntham D, Chansriwong P, Sirachainan E, Reungwetwattana T. Cancer Biomark. 2023;36(1):71-82.

• Real-world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis.

  Dechaphunkul A, Danchaivijitr P, Jiratrachu R, Dechaphunkul T, Sookthon C, Jiarpinitnun C, Paoin C, Setakornnukul J, Suktitipat B, Pattaranutaporn P, Ngamphaiboon N. Asia Pac J Clin Oncol. 2023 Feb;19(1):51-61.

• Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

  Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Cruz C, Callery JJ, Singh S, Saroj M, Kruabkontho V, Ngernseng T, Tanglakmankhong N, Tubprasert J, Abdad MY, Madmanee W, Kouhathong J, Suwannasin K, Pagornrat W, Piaraksa N, Hanboonkunupakarn P, Hanboonkunupakarn B, Poovorawan K, Potaporn M, Srisubat A, Loharjun B, Taylor WRJ, Chotivanich V, Chotivanich K, Imwong M, Pukrittayakamee S, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Lancet Infect Dis. 2024 Jan;24(1):36-45.

• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.

  Koppikar S, Oaknin A, Babu KG, Lorusso D, Gupta S, Wu LY, Rajabto W, Harano K, Hong SH, Malik RA, Strebel H, Aggarwal IM, Lai CH, Dejthevaporn T, Tangjitgamol S, Cheng WF, Chay WY, Benavides D, Hashim NM, Moon YW, Yunokawa M, Anggraeni TD, Wei W, Curigliano G, Maheshwari A, Mahantshetty U, Sheshadri S, Peters S, Yoshino T, Pentheroudakis G. ESMO Open. 2023 Feb;8(1):100774.

• Active Smokers Are at Higher Risk of COVID-19 Death: A Systematic Review and Meta-analysis.

  Patanavanich R, Siripoon T, Amponnavarat S, Glantz SA. Nicotine Tob Res. 2023 Jan 5;25(2):177-184.

• Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.

  Oranratnachai S, Rattanasiri S, Sirachainan E, Tansawet A, Raunroadroong N, McKay GJ, Attia J, Thakkinstian A. Cancer Med. 2023 Feb;12(3):3046-3053.

• Predictive Factors for the Survival Outcomes of Preoperative Chemotherapy in Patients with Resectable and Borderline Resectable Colorectal Cancer with Liver Metastasis.

  Inworn N, Senavat P, Aleenajitpong N, Chingchaimaneesri M, Siripoon T, Srirattanapong S, Suragul W, Ngamphaiboon N. Asian Pac J Cancer Prev. 2023 Sep 1;24(9):3037-3047.

• A new era of the Asian clinical research network: a report from the ATLAS international symposium.

  Terada M, Nakamura K, Matsuda T, Okuma HS, Sudo K, Yusof A, Imasa M, Sirachainan E, Anh PT, Fujiwara Y, Yamamoto N, Voon PJ, Chokephaibulkit K, Shibata T, Inoue M, Mano H, Shimoi T, Sriuranpong V, Yonemori K, Shimada K. Jpn J Clin Oncol. 2023 Jun 29;53(7):619-628.

• Unusual manifestation of gastric adenocarcinoma presenting with lymphedema, chylothorax, and chylous ascites.

  Wongrukmit S, Ngamphaiboon N, Kiranantawat K, Suwanthanma W, Plumworasawat S, Boonsakan P, Pongtippan A, Phanachet P, Warodomwichit D, Shantavasinkul PC. Clin J Gastroenterol. 2023 Dec;16(6):822-828.

• Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.

  Dejthevaporn T, Patanayindee P. Breast Cancer (Auckl). 2023 Jul 31;17:11782234231186869.

• Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report.

  Mavichak W, Laowalert S, Ativitavas T, Rungprai D. Transplant Direct. 2023 Jun 28;9(7):e1509.

 

2022 (19)

1. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

   Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. J Clin Oncol. 2023 Feb 1;41(4):790-802.

• Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.

  Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. J Clin Oncol. 2022 Jul 20;40(21):2321-2332.

• Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.

  Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. Ann Oncol. 2023 Mar;34(3):251-261.

• Strongyloides stercoralis: A Neglected but Fatal Parasite.

  Luvira V, Siripoon T, Phiboonbanakit D, Somsri K, Watthanakulpanich D, Dekumyoy P. Trop Med Infect Dis. 2022 Oct 17;7(10):310.

• Immunotherapy and Biomarkers in Sarcoma.

  Dajsakdipon T, Siripoon T, Ngamphaiboon N, Ativitavas T, Dejthevaporn T. Curr Treat Options Oncol. 2022 Mar;23(3):415-438.

• Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

  Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Oral Oncol. 2022 May;128:105815.

• Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.

  Charonpongsuntorn C, Tanasanvimon S, Korphaisarn K, Payapwattanawong S, Siripoon T, Pakvisal N, Juengsamarn J, Phaibulvatanapong E, Chindaprasirt J, Prasongsook N, Udomdamrongkul K, Ngamphaiboon N, Sirachainan E. JCO Glob Oncol. 2022 Nov;8:e2200205.

• Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.

  Saifon W, Sensorn I, Trachu N, Oranratnachai S, Charoenyingwattana A, Runcharoen C, Monnamo N, Sukkasem W, Inchareon P, Suwatanapongched T, Chansriwong P, Ativitavas T, Panvichian R, Chantratita W, Reungwetwattana T. BMC Cancer. 2022 Sep 8;22(1):963.

• Clinical Study of Long-Term Survival in Colorectal Cancer Patients in Thailand: A 10-Year Follow-Up.

  Thokanit NS, Promchana S, Thonkamdee T, Jitkasikorn P, Siripoon T, Ngamphaiboon N, Sirachainan E. Iran J Public Health. 2022 Nov;51(11):2538-2548.

• Evidence of transmission of influenza A and influenza B co-infection in healthcare workers.

  Luvira V, Thippornchai N, Leaungwutiwong P, Siripoon T, Piroonamornpun P, Phumratanaprapin W, Iamsirithaworn S. J Infect Dev Ctries. 2022 Jul 28;16(7):1199-1205.

• Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.

  Archwamety A, Teeyapun N, Siripoon T, Poungvarin N, Tanasanvimon S, Sirachainan E, Akewanlop C, Korphaisarn K. Front Oncol. 2022 Feb 15;12:813009.

• Prevalence, Risk Factors, and Prognosis of Liver Involvement in Adult Patients with Chikungunya in Thailand.

  Srikirin P, Siripoon T, Charoenpong L, Soonthornworasiri N, Matsee W, Kittitrakul C, Tangkijvanich P, Charunwatthana P, Poovorawan K. Am J Trop Med Hyg. 2022 Oct 17;107(5):1107-1113.

• Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients.

  Atasilp C, Lenavat R, Vanwong N, Chansriwong P, Sirachainan E, Reungwetwattana T, Jinda P, Aiempradit S, Sirilerttrakul S, Chamnanphon M, Puangpetch A, Sankuntaw N, Satapornpong P, Sukasem C. Front Oncol. 2022 Jul 15;12:916650.

• Temporal Trend of COVID-19 Vaccine Acceptance and Factors Influencing International Travellers.

  Onwan M, Matsee W, Lawpoolsri S, Pisutsan P, Siripoon T, Punrin S, Piyaphanee W. Trop Med Infect Dis. 2022 Sep 2;7(9):223.

• Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

  Ngamprasertchai T, Kajeekul R, Sivakorn C, Ruenroegnboon N, Luvira V, Siripoon T, Luangasanatip N. Infect Dis Ther. 2022 Feb;11(1):231-248.

• Real-world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis.

  Dechaphunkul A, Danchaivijitr P, Jiratrachu R, Dechaphunkul T, Sookthon C, Jiarpinitnun C, Paoin C, Setakornnukul J, Suktitipat B, Pattaranutaporn P, Ngamphaiboon N. Asia Pac J Clin Oncol. 2023 Feb;19(1):51-61.

• Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.

  Oranratnachai S, Rattanasiri S, Sirachainan E, Tansawet A, Raunroadroong N, McKay GJ, Attia J, Thakkinstian A. Cancer Med. 2023 Feb;12(3):3046-3053.

• Benefits of prophylactic percutaneous gastrostomy in patients with nasopharyngeal cancer receiving concurrent chemoradiotherapy: A multicenter analysis.

  Dechaphunkul T, Ngamphaiboon N, Danchaivijitr P, Jiratrachu R, Geater SL, Pattaranutaporn P, Jiarpinitnun C, Setakornnukul J, Suktitipat B, Dechaphunkul A. Am J Otolaryngol. 2022 Mar-Apr;43(2):103356.

• Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories.

  Ithimakin S, Parinyanitikul N, Kim SB, Yap YS, Tsang J, Soong IS, Ozaki Y, Ohno S, Ono M, Chan JJ, Cheng HCS, Dejthevaporn T; BIG-Asia Collaboration. J Breast Cancer. 2022 Jun;25(3):207-217.

 

2021

2020

1. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

2. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. PMID: 31751012 Clinical Trial.

3. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A. JAMA Netw Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. PMID: 33074326 Free PMC article. Clinical Trial.

4. Lung Cancer in Thailand. Reungwetwattana T, Oranratnachai S, Puataweepong P, Tangsujaritvijit V, Cherntanomwong P. J Thorac Oncol. 2020 Nov;15(11):1714-1721. doi: 10.1016/j.jtho.2020.04.024. Epub 2020 Oct 23. PMID: 33148410 No abstract available.

5. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Sirilerttrakul S, Chamnanphon M, Puangpetch A, Sukasem C. Sci Rep. 2020 Aug 10;10(1):13486. doi: 10.1038/s41598-020-70351-0. PMID: 32778670 Free PMC article.

6. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Sueangoen N, Tantiwetrueangdet A, Panvichian R. Cell Biosci. 2020 Mar 16;10:41. doi: 10.1186/s13578-020-00407-1. eCollection 2020. PMID: 32190291 Free PMC article.

7. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. J Thorac Oncol. 2020 Sep;15(9):1484-1496. doi: 10.1016/j.jtho.2020.04.019. Epub 2020 Apr 28. PMID: 32360579 Free article.

8. Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma. Phruttinarakorn B, Reungwetwattana T, Incharoen P. Mol Clin Oncol. 2020 Sep;13(3):12. doi: 10.3892/mco.2020.2082. Epub 2020 Jul 1. PMID: 32754326 Free PMC article.

9. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. J Thorac Oncol. 2020 Mar;15(3):324-343. doi: 10.1016/j.jtho.2019.10.022. Epub 2019 Nov 13. PMID: 31733357 Free article. Review.

10. Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand. Ngamphaiboon N, Dechaphunkul A, Setakornnukul J, Dechaphunkul T, Jiratrachu R, Suktitipat B, Jiarpinitnun C, Pattaranutaporn P, Danchaivijitr P. BMC Cancer. 2020 Jun 3;20(1):518. doi: 10.1186/s12885-020-07024-8. PMID: 32493288 Free PMC article.

11. Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial. Koonrungsesomboon N, Ngamphaiboon N, Townamchai N, Teeyakasem P, Charoentum C, Charoenkwan P, Natesirinilkul R, Sathitsamitphong L, Ativitavas T, Chaiyawat P, Klangjorhor J, Hongeng S, Pruksakorn D. BMC Cancer. 2020 Mar 30;20(1):268. doi: 10.1186/s12885-020-06751-2. PMID: 32228535 Free PMC article. Clinical Trial.

12. Characteristics and Impact of HPV-Associated p16 Expression on Head and Neck Squamous Cell Carcinoma in Thai Patients. Jiarpinitnun C, Larbcharoensub N, Pattaranutaporn P, Chureemas T, Juengsamarn J, Trachu N, Lukerak S, Chansriwong P, Ngamphaiboon N. Asian Pac J Cancer Prev. 2020 Jun 1;21(6):1679-1687. doi: 10.31557/APJCP.2020.21.6.1679. PMID: 32592364 Free PMC article.

13. The Effects of the Respiratory Rehabilitation Program on Perceived Self-Efficacy and Dyspnea in Patients with Lung Cancer. Saetan P, Chaiviboontham S, Pokpalagon P, Chansriwong P. Asian Nurs Res (Korean Soc Nurs Sci). 2020 Dec;14(5):277-285. doi: 10.1016/j.anr.2020.08.010. Epub 2020 Sep 8. PMID: 32916339 Free article.

14. MALAT1 Decreases the Sensitivity of Head and Neck Squamous Cell Carcinoma Cells to Radiation and Cisplatin. Kangboonruang K, Wongtrakoongate P, Lertsuwan K, Khachonkham S, Changkaew P, Tangboonduangjit P, Siripoon T, Ngamphaiboon N, Chairoungdua A. Anticancer Res. 2020 May;40(5):2645-2655. doi: 10.21873/anticanres.14235. PMID: 32366409

15. Efficacy and safety of pharmacological cachexia interventions: systematic review and network meta-analysis. Saeteaw M, Sanguanboonyaphong P, Yoodee J, Craft K, Sawangjit R, Ngamphaiboon N, Shantavasinkul PC, Subongkot S, Chaiyakunapruk N. BMJ Support Palliat Care. 2021 Mar;11(1):75-85. doi: 10.1136/bmjspcare-2020-002601. Epub 2020 Nov 27. PMID: 33246937

16. Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment. Genuino AJ, Gloria MAJ, Chaikledkaew U, Reungwetwattana T, Thakkinstian A. Expert Rev Pharmacoecon Outcomes Res. 2020 Sep 24:1-10. doi: 10.1080/14737167.2020.1819795. Online ahead of print. PMID: 32972260

17. Bilateral Scrotal Masses as a Clue to Diagnosis of Genetic Disease. Saowapa S, Ativitavas T, Sriphrapradang C. Am J Med Sci. 2020 Apr;359(4):250-251. doi: 10.1016/j.amjms.2019.11.014. Epub 2019 Nov 30. PMID: 31902518 No abstract available.

18. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.atimarattananan T, Nongnuch A, Pattaranutaporn P, Unwanatham N, Jiarpinitnun C, Ngamphaiboon N. Support Care Cancer. 2021 Feb;29(2):877-887. doi: 10.1007/s00520-020-05566-y. Epub 2020 Jun 10. PMID: 32524284

19. Home-based chemotherapy for stage III colon cancer patients in Thailand: Cost-utility and budget impact analyses. Kulthanachairojana N, Chansriwong P, Thokanit NS, Sirilerttrakul S, Wannakansophon N, Taychakhoonavudh S. Cancer Med. 2021 Feb;10(3):1027-1033. doi: 10.1002/cam4.3690. Epub 2020 Dec 30.

 

2019

1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. PMID: 31679945 Clinical Trial.

2. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

3. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. PMID: 31751012 Clinical Trial.

4. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y. J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18. PMID: 30240852 Free article.

5. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. enuino AJ, Chaikledkaew U, The DO, Reungwetwattana T, Thakkinstian A. Expert Rev Clin Pharmacol. 2019 Aug;12(8):815-824. doi: 10.1080/17512433.2019.1637252. Epub 2019 Jul 9. PMID: 31287333 Free PMC article.

6. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10. PMID: 30981696 Clinical Trial.

7. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. J Thorac Oncol. 2020 Mar;15(3):324-343. doi: 10.1016/j.jtho.2019.10.022. Epub 2019 Nov 13. PMID: 31733357 Free article. Review.

8. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Ngamphaiboon N, Chureemas T, Siripoon T, Arsa L, Trachu N, Jiarpinitnun C, Pattaranutaporn P, Sirachainan E, Larbcharoensub N. Med Oncol. 2019 Jan 21;36(2):21. doi: 10.1007/s12032-018-1241-1. PMID: 30666437

9. Bilateral Scrotal Masses as a Clue to Diagnosis of Genetic Disease. Saowapa S, Ativitavas T, Sriphrapradang C. Am J Med Sci. 2020 Apr;359(4):250-251. doi: 10.1016/j.amjms.2019.11.014. Epub 2019 Nov 30. PMID: 31902518 No abstract available.

10. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. Genuino AJ, Chaikledkaew U, Guerrero AM, Reungwetwattana T, Thakkinstian A. BMC Health Serv Res. 2019 Nov 21;19(1):874. doi: 10.1186/s12913-019-4715-8. PMID: 31752849 Free PMC article.

11. Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma. Bunbanjerdsuk S, Vorasan N, Saethang T, Pongrujikorn T, Pangpunyakulchai D, Mongkonsiri N, Arsa L, Thokanit N, Pongsapich W, Anekpuritanang T, Ngamphaiboon N, Jinawath A, Sunpaweravong S, Pisitkun T, Suktitipat B, Jinawath N. Mod Pathol. 2019 Jul;32(7):943-956. doi: 10.1038/s41379-019-0211-2. Epub 2019 Feb 8. PMID: 30737471

12. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC. Incharoen P, Charonpongsuntorn C, Saowapa S, Sirachainan E, Dejthevaporn T, Kampreasart K, Trachu N, Muntham D, Reungwetwattana T. Asian Pac J Cancer Prev. 2019 Dec 1;20(12):3581-3589. doi: 10.31557/APJCP.2019.20.12.3581. PMID: 31870097 Free PMC article.

13. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib. Kongsuphon N, Soukavanitch M, Teeraaumpornpunt N, Konmun J, Ativitavas T, Ngamphaiboon N. J Gastrointest Cancer. 2019 Sep;50(3):601-603. doi: 10.1007/s12029-018-0067-6.

 

2018

1. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. PMID: 29151359 Free article. Clinical Trial.

2. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. PMID: 29182496 Free PMC article. Clinical Trial.

3. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. Online ahead of print. PMID: 30153097

4. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y. J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18. PMID: 30240852 Free article.

5. Progress in the Management of Malignant Pleural Mesothelioma in 2017. McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T. J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. PMID: 29524617 Free PMC article. Review.

6. Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues. Tantiwetrueangdet A, Panvichian R, Sornmayura P, Sueangoen N, Leelaudomlipi S. Med Oncol. 2018 Aug 16;35(10):127. doi: 10.1007/s12032-018-1191-7. PMID: 30116916 Free PMC article.

7. Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type. Shiao MS, Chiablaem K, Charoensawan V, Ngamphaiboon N, Jinawath N. Front Genet. 2018 Aug 15;9:309. doi: 10.3389/fgene.2018.00309. eCollection 2018. PMID: 30158952 Free PMC article. Review.

8. Missed opportunity? Worsening breathlessness as a harbinger of death: a cohort study. Currow DC, Smith JM, Chansriwong P, Noble SIR, Nikolaidou T, Ferreira D, Johnson MJ, Ekström M. Eur Respir J. 2018 Sep 6;52(3):1800684. doi: 10.1183/13993003.00684-2018. Print 2018 Sep. PMID: 30049740 Free article.

9. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. Larbcharoensub N, Mahaprom K, Jiarpinitnun C, Trachu N, Tubthong N, Pattaranutaporn P, Sirachainan E, Ngamphaiboon N. Am J Clin Oncol. 2018 Dec;41(12):1204-1210. doi: 10.1097/COC.0000000000000449. PMID: 29672367

10. Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues. Tantiwetrueangdet A, Panvichian R, Wongwaisayawan S, Sueangoen N, Lertsithichai P. Med Oncol. 2018 Oct 3;35(12):149. doi: 10.1007/s12032-018-1210-8. PMID: 30284063 Free PMC article.

11. Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Puangpetch A, Prommas S, Sirilerttrakul S, Rerkarmnuaychoke B, Wongwaisayawan S, Sukasem C. J Clin Lab Anal. 2018 Jan;32(1):e22217. doi: 10.1002/jcla.22217. Epub 2017 Apr 10.

 

2017

1. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. PMID: 29151359 Free article. Clinical Trial.

2. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. PMID: 29182496 Free PMC article. Clinical Trial.

3. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Reungwetwattana T, Liang Y, Zhu V, Ou SI. Lung Cancer. 2017 Jan;103:27-37. doi: 10.1016/j.lungcan.2016.11.011. Epub 2016 Nov 15. PMID: 28024693 Free article. Review.

4. Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population. Trachu N, Sirachainan E, Larbcharoensub N, Rattanadech W, Detarkom S, Monnamo N, Kamprerasart K, MunTham D, Sukasem C, Reungwetwattana T. Onco Targets Ther. 2017 Oct 11;10:4955-4968. doi: 10.2147/OTT.S143982. eCollection 2017. PMID: 29066915 Free PMC article.

5. A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Konmun J, Danwilai K, Ngamphaiboon N, Sripanidkulchai B, Sookprasert A, Subongkot S. Med Oncol. 2017 Apr;34(4):69. doi: 10.1007/s12032-017-0931-4. Epub 2017 Mar 27. PMID: 28349496 Clinical Trial.

6. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, Yau T, Gibbs P, Wang X, Doval DC, Oh ST, Shim BY, Gorospe C, Wang HM, Sirachainan E, Hill A, Suh KW, Beier F, Chatterjee S, Lim R. Clin Colorectal Cancer. 2017 Jun;16(2):e73-e88. doi: 10.1016/j.clcc.2016.08.005. Epub 2016 Sep 7. PMID: 27780749 Free article. Clinical Trial.

7. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers. Tamtai A, Jiarpinitnun C, Hiranyatheb P, Unwanatham N, Sirachainun E, Supsamutchai C, Pattaranutaporn P, Ngamphaiboon N. Med Oncol. 2017 Sep;34(9):157. doi: 10.1007/s12032-017-1017-z. Epub 2017 Aug 7. PMID: 28785986

8. Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Puangpetch A, Prommas S, Sirilerttrakul S, Rerkarmnuaychoke B, Wongwaisayawan S, Sukasem C. J Clin Lab Anal. 2018 Jan;32(1):e22217. doi: 10.1002/jcla.22217. Epub 2017 Apr 10. PMID: 28393405 Free PMC article.

9. Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma. Panomuppakarn N, Witoonpanich P, Waisayarat J, Jiarpinitnun C, Ativitavas T, Ngamphaiboon N. Clin Case Rep. 2017 Aug 24;5(10):1628-1633. doi: 10.1002/ccr3.1123. eCollection 2017 Oct. PMID: 29026560 Free PMC article.

10. Breast reconstruction in pregnancy: a case report of multidisciplinary team approach in immediate autologous flap reconstruction for pregnancy-associated breast cancer. Chirappapha P, Thaweepworadej P, Ngamphaiboon N, Sukprasert M, Sukarayothin T, Leesombatpaiboon M. Clin Case Rep. 2017 Jul 20;5(9):1450-1453. doi: 10.1002/ccr3.1092. eCollection 2017 Sep.

 

2016

1. Scientific Advances in Lung Cancer 2015. Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. PMID: 27013409 Free article. Review.

2. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Reungwetwattana T, Liang Y, Zhu V, Ou SI. Lung Cancer. 2017 Jan;103:27-37. doi: 10.1016/j.lungcan.2016.11.011. Epub 2016 Nov 15. PMID: 28024693 Free article. Review.

3. Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research. Jinawath N, Bunbanjerdsuk S, Chayanupatkul M, Ngamphaiboon N, Asavapanumas N, Svasti J, Charoensawan V. J Transl Med. 2016 Nov 22;14(1):324. doi: 10.1186/s12967-016-1078-3. PMID: 27876057 Free PMC article. Review.

4. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy. Incharoen P, Reungwetwattana T, Saowapa S, Kamprerasart K, Pangpunyakulchai D, Arsa L, Jinawath A. World J Surg Oncol. 2016 May 3;14:139. doi: 10.1186/s12957-016-0893-6. PMID: 27142166 Free PMC article.

5. ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. Sensorn I, Sukasem C, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Pinthong D, Wongwaisayawan S. Onco Targets Ther. 2016 Apr 12;9:2121-9. doi: 10.2147/OTT.S100905. eCollection 2016. PMID: 27110128 Free PMC article.

6. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S, Sukasem C. Drug Metab Pharmacokinet. 2016 Feb;31(1):90-94. doi: 10.1016/j.dmpk.2015.12.004. Epub 2015 Dec 31. PMID: 26830078

7. Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. Reungwetwattana T, Adjei AA. J Thorac Oncol. 2016 Dec;11(12):2048-2050. doi: 10.1016/j.jtho.2016.10.008. PMID: 27866633 Free article. No abstract available.

8. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, Yau T, Gibbs P, Wang X, Doval DC, Oh ST, Shim BY, Gorospe C, Wang HM, Sirachainan E, Hill A, Suh KW, Beier F, Chatterjee S, Lim R. Clin Colorectal Cancer. 2017 Jun;16(2):e73-e88. doi: 10.1016/j.clcc.2016.08.005. Epub 2016 Sep 7. PMID: 27780749 Free article. Clinical Trial.

9. Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers. Sukasem C, Atasilp C, Chansriwong P, Chamnanphon M, Puangpetch A, Sirachainan E. J Clin Lab Anal. 2016 Jan;30(1):84-9. doi: 10.1002/jcla.21820. Epub 2014 Dec 26. PMID: 25545261 Free PMC article.

10. DCE-MRI-Derived Parameters as Predictors of Response to Neo-Adjuvant Chemoradiation Treatment of Rectal Carcinoma. Phongkitkarun S, Tohmad U, Larbcharoensub N, Sumbunnanondha K, Swangsilpa T, Sirachainan E. J Med Assoc Thai. 2016 Mar;99(3):338-47. PMID: 27276746

11. Sister Mary Joseph nodule caused by metastatic desmoplastic small round cell tumor: A clinicopathological report. Larbcharoensub N, Pongtippan A, Pangpunyakulchai D, Phongkitkarun S, Lertsithichai P, Dejthevaporn TS. Mol Clin Oncol. 2016 Nov;5(5):557-561. doi: 10.3892/mco.2016.1002. Epub 2016 Aug 24. PMID: 27900084 Free PMC article.

12. Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations. Reungwetwattana T, Ou SH. J Thorac Oncol. 2016 Mar;11(3):281-3. doi: 10.1016/j.jtho.2016.01.005.

 

2015

1. TOP2A amplification and overexpression in hepatocellular carcinoma tissues. Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S. Biomed Res Int. 2015;2015:381602. doi: 10.1155/2015/381602. Epub 2015 Jan 28. PMID: 25695068 Free PMC article.

2. Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Biomed Res Int. 2015;2015:171845. doi: 10.1155/2015/171845. Epub 2015 Sep 7. PMID: 26436086 Free PMC article.

3. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S, Sukasem C. Drug Metab Pharmacokinet. 2016 Feb;31(1):90-94. doi: 10.1016/j.dmpk.2015.12.004. Epub 2015 Dec 31. PMID: 26830078

4. Hospice utilization and end-of-life care in metastatic breast cancer patients at a comprehensive cancer center. O'Connor TL, Ngamphaiboon N, Groman A, Luczkiewicz DL, Kuszczak SM, Grant PC, Kerr CW. J Palliat Med. 2015 Jan;18(1):50-5. doi: 10.1089/jpm.2014.0238. PMID: 25353618

5. Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma. Tulalamba W, Larbcharoensub N, Sirachainan E, Tantiwetrueangdet A, Janvilisri T. Tumour Biol. 2015 Aug;36(8):5931-42. doi: 10.1007/s13277-015-3268-7. Epub 2015 Feb 28. PMID: 25724187

6. Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand. Darunikorn P, Puataweepong P, Dhanachai M, Dangprasert S, Swangsilpa T, Sitathanee C, Jiarpinitnun C, Pattaranutaporn P, Boonyawan K, Chansriwong P. Asian Pac J Cancer Prev. 2015;16(16):7315-9. doi: 10.7314/apjcp.2015.16.16.7315. PMID: 26514530 Free article.

7. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Ngamphaiboon N, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. Invest New Drugs. 2015 Feb;33(1):225-32. doi: 10.1007/s10637-014-0174-6. Epub 2014 Nov 5. PMID: 25371323 Clinical Trial.

8. MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval. Reungwetwattana T, Ou SH. Transl Lung Cancer Res. 2015 Dec;4(6):820-4. doi: 10.3978/j.issn.2218-6751.2015.12.03.

 

2014

1. Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. Jitawatanarat P, O'Connor TL, Kossoff EB, Levine EG, Chittawatanarat K, Ngamphaiboon N. J Breast Cancer. 2014 Dec;17(4):356-62. doi: 10.4048/jbc.2014.17.4.356. Epub 2014 Dec 26. PMID: 25548584 Free PMC article.

2. Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers. Sukasem C, Atasilp C, Chansriwong P, Chamnanphon M, Puangpetch A, Sirachainan E. J Clin Lab Anal. 2016 Jan;30(1):84-9. doi: 10.1002/jcla.21820. Epub 2014 Dec 26. PMID: 25545261 Free PMC article.

3. Esthesioneuroblastoma metastasis to the breast: A case report and review of the literature. Larbcharoensub N, Kanoksil W, Cheewaruangroj W, Wiratkapun C, Sitathanee C, Sirachainan E. Oncol Lett. 2014 Oct;8(4):1505-1508. doi: 10.3892/ol.2014.2403. Epub 2014 Aug 1. PMID: 25202357 Free PMC article.

4. A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region. Soon SS, Lopes G, Lim HY, Wong-Rieger D, Bahri S, Hickinbotham L, Jha A, Ko BS, MacDonell D, Pwu JR, Shih R, Sirachainan E, Suh DC, Wale J, Zhang X, Wee HL. Orphanet J Rare Dis. 2014 Sep 16;9:137. doi: 10.1186/s13023-014-0137-1. PMID: 25223275 Free PMC article.

5. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Ngamphaiboon N, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. Invest New Drugs. 2015 Feb;33(1):225-32. doi: 10.1007/s10637-014-0174-6. Epub 2014 Nov 5. PMID: 25371323 Clinical Trial.

6. A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD, Stella PJ, Marks R, Wright J, Adjei AA. Lung Cancer. 2014 Aug;85(2):245-50. doi: 10.1016/j.lungcan.2014.03.004. Epub 2014 May 1.

 

2013

 

1. Roles of cancer registries in enhancing oncology drug access in the Asia-Pacific region. Soon SS, Lim HY, Lopes G, Ahn J, Hu M, Ibrahim HM, Jha A, Ko BS, Lee PW, Macdonell D, Sirachainan E, Wee HL. Asian Pac J Cancer Prev. 2013;14(4):2159-65. doi: 10.7314/apjcp.2013.14.4.2159. PMID: 23725106 Free article. Review.

2. Targeted therapies in development for non-small cell lung cancer. Reungwetwattana T, Dy GK. J Carcinog. 2013 Dec 31;12:22. doi: 10.4103/1477-3163.123972. eCollection 2013. PMID: 24574860 Free PMC article. Review.

3. Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. Butthongkomvong K, Sirachainan E, Jhankumpha S, Kumdang S, Sukhontharot OU. Asian Pac J Cancer Prev. 2013;14(6):3565-8. doi: 10.7314/apjcp.2013.14.6.3565. PMID: 23886146 Free article.

4. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C. Pharmgenomics Pers Med. 2013 May 24;6:37-48. doi: 10.2147/PGPM.S42330. Print 2013. PMID: 23776391 Free PMC article.

5. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Sensorn I, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D. Pharmgenomics Pers Med. 2013 Aug 26;6:93-8. doi: 10.2147/PGPM.S44006. eCollection 2013.

 

2012

1. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2012 Jul;13(4):252-66.

3. Panvichian R, Tantiwetrueangdet A, Wongwaisayawan S. et al. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere. Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):367-74
4. Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V. et al. CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenomics Pers Med. 2012;5:149-53
5. Sukasem C, Sirachainan E, Chamnanphon M, Pechatanan K, Sirisinha T, Ativitavas T, Panvichian R, Ratanatharathorn V, Trachu N, Chantratita W. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev. 2012;13(9):4549-53

2011

1. Reungwetwattana T, Eadens MJ, Molina JR.Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. Semin Respir Crit Care Med. 2011 Feb;32(1):78-93
2. Larbcharoensub N, Sornmayura P, Sirachainan E. et al. Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma. Histopathology. 2011 Aug;59(2):235-46
3. Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, et al. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:4-12. Erratum in: Asia Pac J Clin Oncol. 2011 Sep;7(3):321. Thitiya, Sirisinha [corrected to Sirisinha, Thitiya].

2010

1. Chansriwong P, Sirisinha T. Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital. J Med Assoc Thai. 2010 Feb;93

2009

1. Niparuck P, Ungkanont A, Ativitavas T et al. The combined use of Flu/ATG in nonmyeloablative SCT for severe aplastic anemia with multiple earlier transfusions. Bone Marrow Transplant 2009 Jun; 43(11): 887-9

2008

1. Ativitavas T, Jirasiritham S, Ngorsakun P et al. Malignancies in renal transplant patients: 15 years experience in Thailand. Transplant Proc. 2008 Sep;40(7):2403-4
2. Larbcharoensub N, Leopairat J, Sirachainan E. et al. Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum Pathol. 2008 Jun;39(6):837-45
3. Phongkitkarun S, Phaisanphrukkun C, Jatchavala J, Sirachainan E. et al. Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate. World J Gastroenterol. 2008 Feb 14;14(6):892-8

2007

1. Tantiwetrueangdet A, Panvichian R, Sornmayura P. et al. Fluorescence in situ hybridization method in isolated single nuclei extracted from paraffin-embedded hepatocellular carcinoma tissues. J Med Assoc Thai. 2007 Feb;90(2):363-8.
2. Dhanachai M, Kraiphibul P, Dangprasert S, Puataweepong P, Narkwong L, Laothamatas J, Kulapraditharom B, Sirachainan E, Yongvithisatid P.Fractionated stereotactic radiotherapy in residual or recurrent nasopharyngeal carcinoma. Acta Oncol. 2007;46(6):828-33

2006

1. Niticharoenpong K, Chalermsanyakorn P, Panvichian R et al. Acute deterioration of renal function induced by star fruit ingestion in a patient with chronic kidney disease. J Nephrol. 2006 Sep-Oct;19(5):682-6.
2. Silpakit C, Sirilerttrakul S, Jirajarus M, Sirisinha T, Sirachainan E, Ratanatharathorn V. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): validation study of the Thai version. Qual Life Res. 2006 Feb;15(1):167-72

2005

1. Sirachainan E, Sumboonnanonda K, Dangprasert S, Panvichian R, Sirisinha T, Dhanachai M, Pairachvet V, Kraiphibul P, Ratanatharathorn V.Preoperative chemoradiotherapy in locally advanced rectal cancer: Ramathibodi experience. J Med Assoc Thai. 2005 Feb;88(2):162-7
2. Sirisinha T, Sirilertrakul S, Jirajarus M, Ratanatharathorn V. Docetaxel in previously treated non-small cell lung cancer patients: clinical efficacy and quality of life. Southeast Asian J Trop Med Public Health. 2005 Jan;36(1):246-53

2002

1. Sirisinha T, Ratanatharathorn V, Jirajarus M, Sirilerttrakul S, Silpakit C, Sirachainan E, Tanvetyanon T. The European Organization for Research and Treatment of Cancer quality of life questionnaire: translation and reliability study of the Thai version. J Med Assoc Thai. 2002 Nov;85(11):1210-9

2001

1. Ratanatharathorn V, Sirilerttrakul S, Jirajarus M, Silpakit C, Maneechavakajorn J, Sailamai P, Sirisinha T. Quality of life, Functional Assessment of Cancer Therapy-General. J Med Assoc Thai. 2001 Oct;84(10):1430-42.
2. Ratanatharathorn V, Lorvidhaya V, Maoleekoonpairoj S. et el. Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer. 2001 Feb-Mar;31(2-3):257-65

2000

1. Ratanatharathorn V, Sirachainan E, Jirajarus M, Sirilerttrakul S. Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. J Med Assoc Thai. 2000 Oct;83(10):1187-95
2. Sirisriro R1, Boonkitticharoen V, Kraiphibul P, Ratanatharathorn V. et al. Detection of colorectal carcinoma by anti-CEA monoclonal antibody (IOR-CEA1) labeled with 99mTc scintigraphy. Hepatogastroenterology. 2000 Mar-Apr;47(32):405-13
3. Ratanatharathorn V, Sirachainan E, Jirajarus M. Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell lung cancer. J Med Assoc Thai. 2000 Sep;83(9):1059-67
4. Ratanatharathorn V, Lorvidhaya V, Kraipiboon P, el al. Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report. J Med Assoc Thai. 2000 Jan;83(1):85-92
5. Ungkanont A, Jootar S, Ratanatharathorn V, Chiernsilp A.High dose chemotherapy and peripheral blood stem cell transplantation for high risk primary breast cancer: a single center experience in Thailand. Asian Pac J Allergy Immunol. 2000 Dec;18(4):215-20

1999

1. Laohavinij S, Maoleekoonpairoj S, Cheirsilpa A, Maneechavakajorn J, Sirachainant E, Arpornvivat W, Jaisathaporn K, Ratanatharathorn V.Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. Lung Cancer. 1999 Dec;26(3):175-85.

1998

1. Ratanatharathorn V, Jirajarus M, Sirachainan E et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a preliminary study. J Med Assoc Thai. 1998 Oct;81(10):763-71
2. Visuthikosol V, Kruavit A, Nitiyanant P, Pochanugool L, Ratanatharathorn V. Salvage treatment for sarcomas of the hand Ann Plast Surg. 1998 Jun;40(6):637-40

1997

1. Pochanugool L1, Sangthawan D, Subhadharaphandou T, Dangprasert S, Hathirat P, Sirikulchayanonta V, Ratanatharathorn V. et al. Osteosarcoma: a study of 130 cases. J Med Assoc Thai. 1997 Mar;80(3):153-9.

1994

1. Cheirsilpa A1, Ratanatharathorn V, Sinlarat P. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy. J Med Assoc Thai. 1994 Apr;77(4):201-6

1991

1. Pochanugool L1, Nontasut S, Subhadharaphandou T, Hathirat P, Sirikulchayanonta V, Ratanatharathorn V, Yuktanonda P. Multidisciplinary "limb salvage" treatment of osteosarcoma. J Med Assoc Thai. 1991 Sep;74(9):404-11
2. Kraiphibul P1, Atichartakarn V, Clongsusuek P, Kulapaditharom B, Ratanatharathorn V, Isarangkul W. Nasopharyngeal carcinoma: results of treatment by radiotherapy vs chemotherapy plus radiotherapy. J Med Assoc Thai. 1991 Sep;74(9):391-6

1988

1. Atichartakarn V1, Kraiphibul P, Clongsusuek P, Pochanugool L, Kulapaditharom B, Ratanatharathorn V. Nasopharyngeal carcinoma: result of treatment with cis-diamminedichloroplatinum II, 5 fluorouracil, and radiation therapy. Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):461-9.